Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
22 results
D1.428 - Fungal Microbiome Diversity in Urban Forest Decreases Asthma and Allergic Inflammation
D1.431 - Associations of the composition of intestinal microbiota with the initial manifestations of IgE-mediated food allergy in children 6-12 months old
D1.433 - The effect of preventive administration of probiotic strain E. coli 083:H24:K31 on selected immune characteristics of eight-year-old children
D3.34 - Cephalosporine drug provocation in a population of children with confirmed serum sickness-like reaction to amoxicillin
D3.35 - Severe atopic dermatitis poorly controlled, or something else?
D3.36 - Contact allergy to sodium metabisulfite in Singapore: A single-center retrospective study of patch test data from 2004 to 2021
D3.37 - Beware of the Rare: AGEP
D3.39 - Autoimmune Progesterone Dermatitis Case Report
D3.42 - Symmetrical drug-related intertriginous and flexural exanthema related to symptomatic slow-acting drug for osteoarthritis (SYSADOA) – a case report
D3.44 - The Role of Medical History and Diagnostic Testing in Identifying Post-Surgical Allergic Reactions
D3.45 - Perioperative Immediate Hypersensitivity Reactions: First Chilean Cohort Study 2020-2024 Clinical Hospital University of Chile
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
D3.415 - Clinical manifestations of Hereditary alpha-tryptasemia (HaT) in Patients with Mast Cell Activation Syndromes
D3.416 - Hereditary Alpha-Tryptasemia: A Case Series
D3.417 - "Comprehensive Allergological Evaluation and Management of Severe Anaphylaxis to Vespid Venoms: A Case Study"
D3.418 - Modulation of Mast Cell Activation by Histamine H3 and H4 Receptor Antagonists
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download